Skip to content
The BCI Briefing

Funding3 min read

Precision Neuroscience raises $250M to take its surface array beyond thirty days

The Series D, led by Pershing Square, is among the largest rounds for a cortical-surface interface and brings the company's total funding to $430M.

ByThe BCI Briefing

Evidence class: Independent verification

The short version

  • $250M Series D led by Pershing Square, the Ackman Oxman Institute and a life-sciences fund.
  • Proceeds go to the clinical programme, further FDA review and commercial infrastructure.
  • The Layer 7 array is cleared for up to 30 days of use; long-term BCI use is still investigational.

Precision Neuroscience closed a $250M Series D, MedTech Dive reported on 25 September. The round brings total funding to $430M since the company launched in 2021.

The company said it will use the capital to expand its clinical programme, advance the Layer 7 Cortical Interface through the next stages of FDA review and build commercialisation infrastructure. It also described a collaboration with Medtronic to integrate the array with Medtronic's neurosurgical platform.

How solid is this

Round size, investors and total funding as reported by MedTech Dive. Valuation was not disclosed. The 30-day FDA clearance is a marketing clearance for temporary use, not an approval of a permanent implant. Published device data: a 1,024-channel array tested in animal models and in a five-patient intraoperative pilot (Nature Biomedical Engineering).

Independent reporting. Reported by a news organisation or trade publication independent of the subject.

What to watch

  1. 01Regulatory steps that extend the permitted duration of implantation.
  2. 02Chronic human recordings showing signal stability over months.
  3. 03Functional results — control or communication — from people using the array as a BCI.

Sources

  1. 01

    Precision Neuroscience raises $250M for brain-computer interface work (opens in a new tab)

    Independent reportingMedTech Dive25 Sep 2026Checked against source 3 Oct 2026

  2. 02

    Hettick M et al. Nat Biomed Eng 2026;10(6):1206–1221 (opens in a new tab)

    Peer reviewedNature Biomedical Engineering2 Oct 2025Checked against source 3 Oct 2026

    DOI 10.1038/s41551-025-01501-w